This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Organon Pharmaceuticals Usa Inc.
Organon Pharmaceuticals USA Inc., a prominent player in the global healthcare landscape, is headquartered in the United States. Founded in 2021, the company emerged as a spin-off from Merck & Co., focusing on women's health, biosimilars, and other therapeutic areas. With a commitment to advancing healthcare solutions, Organon offers a diverse portfolio of products, including contraceptives and hormone therapies, distinguished by their innovative formulations and patient-centric approach. Operating primarily in North America and expanding into international markets, Organon has quickly established itself as a leader in women's health. The company’s dedication to addressing unmet medical needs has garnered recognition, positioning it as a trusted partner in the pharmaceutical industry. With a strong emphasis on research and development, Organon continues to make significant strides in improving health outcomes for women worldwide.
DitchCarbon Score
How does Organon Pharmaceuticals Usa Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Organon Pharmaceuticals Usa Inc.'s score of 72 is higher than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Organon Pharmaceuticals USA Inc., headquartered in the US, currently does not have specific carbon emissions data available for recent years. As a current subsidiary of Merck & Co., Inc., any emissions data or climate commitments may be inherited from its parent company. Merck & Co., Inc. has established various climate initiatives, including Science-Based Targets Initiative (SBTi) commitments, which are cascaded to Organon. However, specific reduction targets or achievements for Organon itself are not detailed. The company is part of a broader industry context that increasingly prioritises sustainability and carbon reduction, yet specific metrics or commitments from Organon Pharmaceuticals USA Inc. remain unspecified at this time.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | 5,760,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Organon Pharmaceuticals Usa Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
